Psychologists in Tecumseh, MI Accepting Medicare
5 Psychologists found. Showing 1 - 5
 Dr. Melanie Ann St Bernard, PHD Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 308 S Maumee St, Tecumseh, MI 49286 Phone: 517-423-6889 Fax: 517-423-6890 |
 Dr. Michael Alan Dosey, PH.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 127 N Evans St, Tecumseh, MI 49286 Phone: 517-424-7345 |
Mr. Harold Stephen Bilotta Jr., MS LLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 308 S Maumee St, Tecumseh, MI 49286 Phone: 517-423-6889 Fax: 517-423-6890 |
David E Lowrance, MS, LLP Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 127 N Evans St, Tecumseh, MI 49286 Phone: 517-673-3274 Fax: 517-264-0383 |
Dr. James Peter Steyaert, PHD Psychologist - Counseling Medicare: Accepting Medicare Assignments Practice Location: 308 S Maumee St, Tecumseh, MI 49286 Phone: 517-423-6889 Fax: 517-423-6890 |
News Archive
HealthEast Mental Health and Addiction Services receives $800,000 charitable gift by V.K. Arrigoni Foundation
HealthEast Mental Health and Addiction Services premier program is the beneficiary of an $800,000 charitable gift by V.K. Arrigoni Foundation. This generous gift gives chemically dependent patients, without insurance or who are underinsured, access to the HealthEast inpatient services at St. Joseph's Hospital in downtown St. Paul and outpatient services at both St. Joseph's Hospital and St. John's Hospital in Maplewood.
Health industry players offer insights, expectations about overhaul's impact
Republicans made major gains in the midterm election, running vowing to "repeal and replace" the health law passed with solely Democratic votes earlier this year.
Novo Nordisk announces $73M expansion of Clayton insulin delivery systems manufacturing facility
Novo Nordisk, a global healthcare company and leader in diabetes care, today announced a $73 million expansion of its Clayton, NC manufacturing facility to accommodate increased production capacity for the Company's insulin delivery devices.
Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b, dose escalation, clinical trial in that country for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
› Verified 7 days ago
Clinical Social Workers
Pharmacists
Dentists
Counselors
Psychologists
Occupational Therapists